BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 34848451)

  • 21. ABT-263 sensitizes TRAIL-resistant hepatocarcinoma cells by downregulating the Bcl-2 family of anti-apoptotic protein.
    Wang G; Zhan Y; Wang H; Li W
    Cancer Chemother Pharmacol; 2012 Mar; 69(3):799-805. PubMed ID: 22037880
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Telomere-homologous G-rich oligonucleotides sensitize human ovarian cancer cells to TRAIL-induced growth inhibition and apoptosis.
    Sarkar S; Faller DV
    Nucleic Acid Ther; 2013 Jun; 23(3):167-74. PubMed ID: 23634944
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bortezomib sensitises TRAIL-resistant HPV-positive head and neck cancer cells to TRAIL through a caspase-dependent, E6-independent mechanism.
    Bullenkamp J; Raulf N; Ayaz B; Walczak H; Kulms D; Odell E; Thavaraj S; Tavassoli M
    Cell Death Dis; 2014 Oct; 5(10):e1489. PubMed ID: 25341043
    [TBL] [Abstract][Full Text] [Related]  

  • 24. TRAIL-induced expression of uPA and IL-8 strongly enhanced by overexpression of TRAF2 and Bcl-xL in pancreatic ductal adenocarcinoma cells.
    Zhou DH; Yang LN; Roder C; Kalthoff H; Trauzold A
    Hepatobiliary Pancreat Dis Int; 2013 Feb; 12(1):94-8. PubMed ID: 23392805
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differential activity of GSK-3 isoforms regulates NF-κB and TRAIL- or TNFα induced apoptosis in pancreatic cancer cells.
    Zhang JS; Herreros-Villanueva M; Koenig A; Deng Z; de Narvajas AA; Gomez TS; Meng X; Bujanda L; Ellenrieder V; Li XK; Kaufmann SH; Billadeau DD
    Cell Death Dis; 2014 Mar; 5(3):e1142. PubMed ID: 24675460
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumor Cell-selective Synergism of TRAIL- and ATRA-induced Cytotoxicity in Breast Cancer Cells.
    Reinhardt A; Liu H; Ma Y; Zhou Y; Zang C; Habbel JP; Possinger K; Eucker J
    Anticancer Res; 2018 May; 38(5):2669-2682. PubMed ID: 29715087
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Loss of MCL1 function sensitizes the MDA-MB-231 breast cancer cells to rh-TRAIL by increasing DR4 levels.
    De Blasio A; Pratelli G; Drago-Ferrante R; Saliba C; Baldacchino S; Grech G; Tesoriere G; Scerri C; Vento R; Di Fiore R
    J Cell Physiol; 2019 Aug; 234(10):18432-18447. PubMed ID: 30912136
    [TBL] [Abstract][Full Text] [Related]  

  • 28. JNK pathway inhibition selectively primes pancreatic cancer stem cells to TRAIL-induced apoptosis without affecting the physiology of normal tissue resident stem cells.
    Recio-Boiles A; Ilmer M; Rhea PR; Kettlun C; Heinemann ML; Ruetering J; Vykoukal J; Alt E
    Oncotarget; 2016 Mar; 7(9):9890-906. PubMed ID: 26840266
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nuclear death receptor TRAIL-R2 inhibits maturation of let-7 and promotes proliferation of pancreatic and other tumor cells.
    Haselmann V; Kurz A; Bertsch U; Hübner S; Olempska-Müller M; Fritsch J; Häsler R; Pickl A; Fritsche H; Annewanter F; Engler C; Fleig B; Bernt A; Röder C; Schmidt H; Gelhaus C; Hauser C; Egberts JH; Heneweer C; Rohde AM; Böger C; Knippschild U; Röcken C; Adam D; Walczak H; Schütze S; Janssen O; Wulczyn FG; Wajant H; Kalthoff H; Trauzold A
    Gastroenterology; 2014 Jan; 146(1):278-90. PubMed ID: 24120475
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ABC294640, a sphingosine kinase 2 inhibitor, enhances the antitumor effects of TRAIL in non-small cell lung cancer.
    Yang J; Yang C; Zhang S; Mei Z; Shi M; Sun S; Shi L; Wang Z; Wang Y; Li Z; Xie C
    Cancer Biol Ther; 2015; 16(8):1194-204. PubMed ID: 26054751
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of preventive and therapeutic activity of novel non-steroidal anti-inflammatory drug, CG100649, in colon cancer: Increased expression of TNF-related apoptosis-inducing ligand receptors enhance the apoptotic response to combination treatment with TRAIL.
    Woo JK; Kang JH; Jang YS; Ro S; Cho JM; Kim HM; Lee SJ; Oh SH
    Oncol Rep; 2015 Apr; 33(4):1947-55. PubMed ID: 25672292
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The pleiotropic profile of the indirubin derivative 6BIO overcomes TRAIL resistance in cancer.
    Braig S; Bischoff F; Abhari BA; Meijer L; Fulda S; Skaltsounis L; Vollmar AM
    Biochem Pharmacol; 2014 Sep; 91(2):157-67. PubMed ID: 25069048
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synergistic proapoptotic activity of recombinant TRAIL plus the Akt inhibitor Perifosine in acute myelogenous leukemia cells.
    Tazzari PL; Tabellini G; Ricci F; Papa V; Bortul R; Chiarini F; Evangelisti C; Martinelli G; Bontadini A; Cocco L; McCubrey JA; Martelli AM
    Cancer Res; 2008 Nov; 68(22):9394-403. PubMed ID: 19010914
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Maritoclax Enhances TRAIL-Induced Apoptosis via CHOP-Mediated Upregulation of DR5 and miR-708-Mediated Downregulation of cFLIP.
    Jeon MY; Min KJ; Woo SM; Seo SU; Choi YH; Kim SH; Kim DE; Lee TJ; Kim S; Park JW; Kwon TK
    Molecules; 2018 Nov; 23(11):. PubMed ID: 30463333
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Emetine enhances the tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of pancreatic cancer cells by downregulation of myeloid cell leukemia sequence-1 protein.
    Han Y; Park S; Kinyua AW; Andera L; Kim KW; Kim I
    Oncol Rep; 2014 Jan; 31(1):456-62. PubMed ID: 24213797
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of the XIAP inhibitor Embelin on TRAIL-induced apoptosis of pancreatic cancer cells.
    Mori T; Doi R; Kida A; Nagai K; Kami K; Ito D; Toyoda E; Kawaguchi Y; Uemoto S
    J Surg Res; 2007 Oct; 142(2):281-6. PubMed ID: 17640673
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of novel molecular regulators of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in breast cancer cells by RNAi screening.
    Garimella SV; Gehlhaus K; Dine JL; Pitt JJ; Grandin M; Chakka S; Nau MM; Caplen NJ; Lipkowitz S
    Breast Cancer Res; 2014 Apr; 16(2):R41. PubMed ID: 24745479
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Small molecule XIAP inhibitors enhance TRAIL-induced apoptosis and antitumor activity in preclinical models of pancreatic carcinoma.
    Vogler M; Walczak H; Stadel D; Haas TL; Genze F; Jovanovic M; Bhanot U; Hasel C; Möller P; Gschwend JE; Simmet T; Debatin KM; Fulda S
    Cancer Res; 2009 Mar; 69(6):2425-34. PubMed ID: 19258513
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HDAC2 attenuates TRAIL-induced apoptosis of pancreatic cancer cells.
    Schüler S; Fritsche P; Diersch S; Arlt A; Schmid RM; Saur D; Schneider G
    Mol Cancer; 2010 Apr; 9():80. PubMed ID: 20398369
    [TBL] [Abstract][Full Text] [Related]  

  • 40. IFN-γ combined with targeting of XIAP leads to increased apoptosis-sensitisation of TRAIL resistant pancreatic carcinoma cells.
    Büneker CK; Yu R; Deedigan L; Mohr A; Zwacka RM
    Cancer Lett; 2012 Mar; 316(2):168-77. PubMed ID: 22104728
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.